Healthcare

Martin Rosenberg, Ph.D.

Dr. Rosenberg is currently the Chief Scientific Officer of Promega Corporation. He joined Promega after retiring in 2001 as Senior Vice President of Anti-Infectives Drug Discovery and Development at GlaxoSmithKline. Before joining SmithKline Pharmaceutical R&D, he spent 10 years at the National Institutes of Health and was a Section Chief in the National Cancer Institute. He currently participates on a variety of academic and industry Scientific Advisory Boards and is the recipient of numerous industry awards. Dr. Rosenberg received his Ph.D. from Purdue and his postdoctoral training at Yale Medical School.